Etanercept (Enbrel®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000395
English
Authors' recommendations:
Etanercept (Enbrel®) is not recommended for use within NHS Wales for the treatment of chronic severe plaque psoriasis in children and adolescents from the age of eight years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies. The cost effectiveness data presented was insufficient for AWMSG to recommend the use of etanercept (Enbrel®) in NHS Wales.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=156345&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Immunoglobulin G
- Psoriasis
- Receptors, Tumor Necrosis Factor
- Immunosuppressive Agents
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.